The Primary Sclerosing Cholangitis drugs in development market research report provides comprehensive information on the therapeutics under development for Primary Sclerosing Cholangitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Primary Sclerosing Cholangitis. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Primary Sclerosing Cholangitis and features dormant and discontinued products.
GlobalData tracks 31 drugs in development for Primary Sclerosing Cholangitis by 30 companies/universities/institutes. The top development phase for Primary Sclerosing Cholangitis is phase ii with 12 drugs in that stage. The Primary Sclerosing Cholangitis pipeline has 28 drugs in development by companies and three by universities/ institutes. Some of the companies in the Primary Sclerosing Cholangitis pipeline products market are: Ipsen, Waterstone Pharmaceuticals (Wuhan) and University of Minnesota.
The key targets in the Primary Sclerosing Cholangitis pipeline products market include Ileal Sodium/Bile Acid Cotransporter, Peroxisome Proliferator Activated Receptor Alpha, and Sodium/Bile Acid Cotransporter.
The key mechanisms of action in the Primary Sclerosing Cholangitis pipeline product include Ileal Sodium/Bile Acid Cotransporter Inhibitor with three drugs in Phase II. The Primary Sclerosing Cholangitis pipeline products include seven routes of administration with the top ROA being Oral and 11 key molecule types in the Primary Sclerosing Cholangitis pipeline products market including Small Molecule, and Peptide.
Primary Sclerosing Cholangitis overview
Primary sclerosing cholangitis (PSC) is a chronic liver disease characterized by a progressive course of cholestasis with inflammation and fibrosis of the intrahepatic and extra hepatic bile ducts. Symptoms include abdominal pain, chills, diarrhea, fatigue, itchiness, and weight loss. The predisposing factors include age and inflammatory bowel diseases. Treatment includes antibiotics and bile-acid-binding drugs.
For a complete picture of Primary Sclerosing Cholangitis’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
